CrystalGenomics Inc Total Assets
CrystalGenomics Inc total assets. Based on the latest financial reports, CrystalGenomics Inc (083790) holds total assets worth ₩212.20 Billion KRW (≈ $143.81 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 083790 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of CrystalGenomics Inc (2011–2024)
Total assets of CrystalGenomics Inc from 2011 to 2024. This chart illustrates how CrystalGenomics Inc's total assets have evolved over time, based on quarterly financial data. See latest CrystalGenomics Inc stock price today for real-time trading data and today's change.
CrystalGenomics Inc - Asset Composition Analysis
CrystalGenomics Inc Total Assets Breakdown (December 2024)
CrystalGenomics Inc total assets breakdown as of December 2024. CrystalGenomics Inc's total assets of ₩212.20 Billion consist of 29.1% current assets and 70.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩42.93 Billion | 0.0% |
| Accounts Receivable | ₩9.35 Billion | 3.6% |
| Inventory | ₩9.18 Billion | 3.5% |
| Property, Plant & Equipment | ₩133.25 Billion | 51.2% |
| Intangible Assets | ₩5.47 Billion | 2.1% |
| Goodwill | ₩3.23 Billion | 1.2% |
Asset Composition Trend (2011–2024)
This chart illustrates how CrystalGenomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 083790 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CrystalGenomics Inc's current assets represent 29.1% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 26.3% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 30.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 51.2% of total assets.
CrystalGenomics Inc Competitors by Total Assets
Key competitors of CrystalGenomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060
|
Korea | ₩80.28 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩575.39 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩267.18 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩125.25 Billion |
|
Aprogen Healthcare & Games Inc
KQ:109960
|
Korea | ₩324.89 Billion |
CrystalGenomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.45 | 0.78 | 2.30 |
| Quick Ratio | 0.34 | 0.74 | 2.16 |
| Cash Ratio | 0.00 | 0.52 | 0.00 |
| Working Capital | ₩-59.61 Billion | ₩-13.15 Billion | ₩92.68 Billion |
CrystalGenomics Inc - Advanced Valuation Insights
This section examines the relationship between CrystalGenomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 7.1% |
| Total Assets | ₩260.47 Billion |
| Market Capitalization | $22.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values CrystalGenomics Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CrystalGenomics Inc's assets grew by 7.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CrystalGenomics Inc (2011–2024)
The table below shows the annual total assets of CrystalGenomics Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩260.47 Billion ≈ $176.51 Million |
+7.14% |
| 2023-12-31 | ₩243.12 Billion ≈ $164.76 Million |
-24.64% |
| 2022-12-31 | ₩322.61 Billion ≈ $218.63 Million |
-3.10% |
| 2021-12-31 | ₩332.93 Billion ≈ $225.62 Million |
+5.04% |
| 2020-12-31 | ₩316.96 Billion ≈ $214.80 Million |
-16.41% |
| 2019-12-31 | ₩379.19 Billion ≈ $256.97 Million |
+47.59% |
| 2018-12-31 | ₩256.92 Billion ≈ $174.11 Million |
+115.06% |
| 2017-12-31 | ₩119.47 Billion ≈ $80.96 Million |
-7.15% |
| 2016-12-31 | ₩128.67 Billion ≈ $87.20 Million |
+1.09% |
| 2015-12-31 | ₩127.28 Billion ≈ $86.26 Million |
+20.02% |
| 2014-12-31 | ₩106.05 Billion ≈ $71.87 Million |
+19.47% |
| 2013-12-31 | ₩88.77 Billion ≈ $60.16 Million |
+62.70% |
| 2012-12-31 | ₩54.56 Billion ≈ $36.97 Million |
-13.35% |
| 2011-12-31 | ₩62.96 Billion ≈ $42.67 Million |
-- |
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more